## Amendments to the Claims

## **Listing of Claims**

- 1. (original) A pharmaceutical composition useful in the treatment or prevention of xenograft rejection comprising
- (a) cyclosporin;
- (b) an immunosuppressant compound selected from the group consisting of mycophenolic acid, a pharmaceutically acceptable salt of mycophenolic acid, and combinations thereof; and(c) rapamycin and/or derivatives thereof.
- 2. (original) A pharmaceutical composition comprising
- (a) cyclosporin;
- (b) an immunosuppressant compound selected from the group consisting of mycophenolic acid, a pharmaceutically acceptable salt of mycophenolic acid, and combinations thereof; and
  (c) rapamycin and/or derivatives thereof
  as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of xenograft rejection.
- 3. (original) A kit of parts comprising a pharmaceutical composition according to claim 1 together with instructions for use in the treatment or prevention of xenograft rejection.
- 4. (cancelled)
- 5. (previously presented) A pharmaceutical composition according to claim 1 wherein the pharmaceutically acceptable salt of mycophenolic acid is MPA sodium salt formulated as an enteric-coated solid oral dosage form.
- 6. (previously presented) A method for the treatment or prevention of xenograft rejection comprising administering a pharmaceutical composition according to claim 1.
- 7-9. (cancelled)
- 10. (previously presented) A pharmaceutical composition according to claim 2 wherein the pharmaceutically acceptable salt of mycophenolic acid is MPA sodium salt formulated as an enteric-coated solid oral dosage form.
- 11. (previously presented) A method for the treatment or prevention of xenograft rejection comprising administering a pharmaceutical composition according to claim 2.